Akribion Therapeutics exits from stealth with €8m seed financing

Akribion is pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion

06-Feb-2025 - Akribion Therapeutics, the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, announces its exit from stealth and the completion of a Seed Financing round raising EUR 8 million to accelerate the development of novel therapeutics based ...

Leyden Labs raises $70 million: Novel class of broadly protective nasal sprays

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses

03-Feb-2025 - Leyden Laboratories B.V. announced it has raised $70M in funding to advance its Mucosal Protection Platform. This non-vaccine approach utilizes broadly protective intranasally administered antibodies to free people from the threat of respiratory viruses, such as influenza and coronaviruses. The ...

Vicebio Announces $100 Million Series B Financing

Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines

30-Sep-2024 - Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, announces a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding ...

try coziness: Very slow malaria pathogens could be suitable as a vaccine

07-Aug-2024 - Scientists from the Heidelberg Medical Faculty at Heidelberg University, the Center for Infectious Diseases at Heidelberg University Hospital and the German Center for Infection Research have successfully tested a new approach for a malaria vaccine in animal experiments: As a vaccine, they used ...

SUANFARMA announces a collaboration with Reyoung Pharmaceutical

The main objective of the collaboration is to introduce generic pharmaceutical ingredients to the market for the treatment of infectious diseases

19-Oct-2023 - SUANFARMA, through its R&D division, celebrates the historic agreement reached with Reyoung Pharmaceutical, a leader in the manufacture of active ingredients since 1966. Reyoung´s decades of experience as an exporter of products worldwide are perfectly aligned with SUANFARMA, which has been ...

Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million

Funding to advance clinical development of its lead candidate in immuno-oncology and infectious diseases

05-Jul-2023 - Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension of €8 ...

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

24-Mar-2023 - Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB ...

Pioneering TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases

Kupando raises €13 million in Series A funding round

27-Sep-2022 - Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, announces today the closing of its Series A funding round which raised €13 million. The funds will be used to complete IND-enabling work and to ...

Centauri Therapeutics closes £24 million GBP Series A investment round

Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates

23-Feb-2022 - Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP (c. 32 million USD) Series A investment round. The funds will support the continued advancement of the ...

Evonik to market and develop new drug delivery platform for mRNA and gene therapy

Evonik and Stanford University sign research collaboration

11-Jun-2021 - Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). This polymer-based platform complements Evonik’s existing portfolio of lipid-based drug delivery, including LNPs. Starting this month, ...